China's National Medical Products Administration (NMPA) approved Shanghai Junshi Biosciences' (HKG:1877) new drug application (NDA) for its cholesterol ongericimab injection, according to a Sunday filing with the Hong Kon bourse.

The drug is meant for the treatment of adult patients with primary hypercholesterolemia (non-familial) and mixed dyslipidemia.

The pharmaceutical stocks were down nearly 5% in Hong Kong and 1% in Shanghai in recent trading.

Price (HKD): $14.58, Change: $-0.72, Percent Change: -4.71%